CRI Worldwide and Lifetree Clinical Research Announce New Company Name: CRI Lifetree
CRI Worldwide, a specialized research organization conentating in psychiatry, pediatrics, pain, and neurology, which recently acquired Lifetree Clinical Research, has united the two companies under the new name, CRI Lifetree. Accompanying the new name is its strategically focused tagline, “Innovative Solutions. Reliable Results.”
The company integrates CRI’s experience in psychiatry and expertise in complex studies with Lifetree’s clinical trial management and site expertise in Phase I-III pain management and abuse liability studies. Bringing the companies together under one unified name streamlines all branding, communication, and SOPs and processes across the two companies.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
